Key result
Percutaneous mitral annuloplasty using the CARILLON device was feasible, with a 13% major adverse event rate at 30 days and significant improvements in 6-minute walk distance (P<0.001).
Why the study?
Does percutaneous mitral annuloplasty with the CARILLON device improve functional mitral regurgitation, exercise tolerance, and quality of life in patients with heart failure?
Population
48 patients with dilated cardiomyopathy, moderate to severe functional mitral regurgitation, ejection…
Design
Cohort
Follow-up
6 months
Authors
Loading...
Should not yet change practice in functional MR; leaves open efficacy pending randomized trials.
Does percutaneous mitral annuloplasty with the CARILLON device improve functional mitral regurgitation, exercise tolerance, and quality of life in patients with heart failure?
Percutaneous mitral annuloplasty with the CARILLON device is feasible and associated with improvements in exercise tolerance and quality of life in patients with heart failure and functional mitral regurgitation.
Schöfer et al. (2009) studied Functional mitral regurgitation in heart failure (n=48). Percutaneous mitral annuloplasty (CARILLON Mitral Contour System) was evaluated on Major adverse events at 30 days. Percutaneous mitral annuloplasty using the CARILLON device was feasible, with a 13% major adverse event rate at 30 days and significant improvements in 6-minute walk distance (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: